Cannabinoids and neuroinflammation

British Journal of Pharmacology

Volumn 141, Issue 5, 2004, Pages 775-785

  Walter, Lisa ^a   Stella, Nephi ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cannabinoid; Glia; Immune cells; Inflammation; Multiple sclerosis

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; AJULEMIC ACID; ANANDAMIDE; CANNABIDIOL; CANNABINOID DERIVATIVE; CANNABINOL; DELTA8 TETRAHYDROCANNABINOL; DEXANABINOL; DRONABINOL; ENDOGENOUS COMPOUND; METHANANDAMIDE; NOLADIN ETHER; PALMIDROL; RIMONABANT; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; DEGENERATIVE DISEASE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENCEPHALITIS; HUMAN; IMMUNOCOMPETENT CELL; MICROGLIA; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; CANNABINOIDS; HUMANS; INFLAMMATION; NEURAL PATHWAYS; NEURODEGENERATIVE DISEASES;

EID: 1842611884     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705667     Document Type: Short Survey

References (170)

1. ABOOD, M.E., RIZVI, G., SALLAPUDI, N. & MCALLISTER, S.D. (2001). Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett., 309, 197-201.
2. AREVALO-MARTIN, A., VELA, J.M., MOLINA-HOLGADO, E., BORRELL, J. & GUAZA, C. (2003). Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci., 23, 2511-2516.
3. BAKER, D., PRYCE, G., CROXFORD, J.L., BROWN, P., PERTWEE, R.G., HUFFMAN, J.W. & LAYWARD, L. (2000). Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature, 404, 84-87.
4. BAKER, D., PRYCE, G., CROXFORD, J.L., BROWN, P., PERTWEE, R.G., MAKRIYANNIS, A., KHANOLKAR, A., LAYWARD, L., FEZZA, F., BISOGNO, T. & DI MARZO, V. (2001). Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J., 15, 300-302.
5. BAYEWITCH, M., AVIDOR-REISS, T., LEVY, R., BARG, J., MECHOULAM, R. & VOGEL, Z. (1995). The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett., 375, 143-147.
6. BAYEWITCH, M., RHEE, M.H., AVIDOR-REISS, T., BREUER, A., MECHOULAM, R. & VOGEL, Z. (1996). (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J. Biol. Chem., 271, 9902-9905.
7. BECHER, B., PRAT, A. & ANTEL, J.P. (2000). Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia, 29, 293-304.
8. +-current. J. Biol. Chem., 278, 46188-46194.
9. BENVENISTE, E.N. (1998). Cytokine actions in the central nervous system. Cytokine Growth Factor Rev., 9, 259-275.
10. BERDYSHEV, E.V., BOICHOT, E., GERMAIN, N., ALLAIN, N., ANGER, J.P. & LAGENTE, V. (1997). Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur. J. Pharmacol., 330, 231-240.
11. BERGLUND, B.A., BORING, D.L., WILKEN, G.H., MAKRIYANNIS, A., HOWLETT, A.C. & LIN, S. (1998). Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups. Prostaglandins Leukot. Essent. Fatty Acids, 59, 111-118.
12. BERRENDERO, F., SANCHEZ, A., CABRANES, A., PUERTA, C., RAMOS, J.A., GARCIA-MERINO, A. & FERNANDEZ-RUIZ, J. (2001). Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse, 41, 195-202.
13. BEZZI, P., DOMERCQ, M., BRAMBILLA, L., GALLI, R., SCHOLS, D., DE CLERCQ, E., VESCOVI, A., BAGETTA, G., KOLLIAS, G., MELDOLESI, J. & VOLTERRA, A. (2001). CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat. Neurosci., 4, 702-710.
14. BISOGNO, T., MAURELLI, S., MELCK, D., DE PETROCELLIS, L. & DI MARZO, V. (1997). Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem., 272, 3315-3323.
15. BOUABOULA, M., BOURRIE, B., RINALDI-CARMONA, M., SHIRE, D., LE FUR, G. & CASELLAS, P. (1995). Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem., 270, 13973-13980.
16. BOUABOULA, M., RINALDI, M., CARAYON, P., CARILLON, C., DELPECH, B., SHIRE, D., LE FUR, G. & CASELLAS, P. (1993). Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem., 214, 173-180.
17. BREIVOGEL, C.S., GRIFFIN, G., DI MARZO, V. & MARTIN, B.R. (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol., 60, 155-163.
18. BRIGHT, J.J. & SRIRAM, S. (2001). Immunotherapy of inflammatory demyelinating diseases of the central nervous system. Immunol. Res., 23, 245-252.
19. BRUCE-KELLER, A.J. (1999). Microglial-neuronal interactions in synaptic damage and recovery. J. Neurosci. Res., 58, 191-201.
20. BUCKLEY, N.E., MCCOY, K.L., MEZEY, E., BONNER, T., ZIMMER, A., FELDER, C.C. & GLASS, M. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol., 396, 141-149.
21. BURSTEIN, S.H. (2000). Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. Curr. Pharmacol. Des., 6, 1339-1345.
22. CABRAL, G.A., HARMON, K.N. & CARLISLE, S.J. (2001). Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. Adv. Exp. Med. Biol., 493, 207-214.
23. CALIGNANO, A., LA RANA, G., GIUFFRIDA, A. & PIOMELLI, D. (1998). Control of pain initiation by endogenous cannabinoids. Nature, 394, 277-281.
24. CAMPBELL, I.L. (1998). Transgenic mice and cytokine actions in the brain: bridging the gap between structural and functional neuropathology. Brain Res. Brain Res. Rev., 26, 327-336.
25. CARAYON, P., MARCHAND, J., DUSSOSSOY, D., DEROCQ, J.M., JBILO, O., BORD, A., BOUABOULA, M., GALIEGUE, S., MONDIERE, P., PENARIER, G., FUR, G.L., DEFRANCE, T. & CASELLAS, P. (1998). Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood, 92, 3605-3615.
26. CARLISLE, S.J., MARCIANO-CABRAL, F., STAAB, A., LUDWICK, C. & CABRAL, G.A. (2002). Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol., 2, 69-82.
27. CARSON, M.J. & SUTCLIFFE, J.G. (1999). Balancing function vs self defense: the CNS as an active regulator of immune responses. J. Neurosci. Res., 55, 1-8.
28. CHAO, C.C., MOLITOR, T.W. & HU, S. (1993). Neuroprotective role of IL-4 against activated microglia. J. Immunol., 151, 1473-1481.
29. CHOPP, M., ZHANG, R.L., CHEN, H., LI, Y., JIANG, N. & RUSCHE, J.R. (1994). Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke, 25, 869-875.
30. COFFEY, R.G., SNELLA, E., JOHNSON, K. & PROSS, S. (1996a). Inhibition of macrophage nitric oxide production by tetrahydrocannabinol in vivo and in vitro. Int. J. Immunopharmacol., 18, 749-752.
31. COFFEY, R.G., YAMAMOTO, Y., SNELLA, E. & PROSS, S. (1996b). Tetrahydrocannabinol inhibition of macrophage nitric oxide production. Biochem. Pharmacol., 52, 743-751.
32. CONDIE, R., HERRING, A., KOH, W.S., LEE, M. & KAMINSKI, N.E. (1996). Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J. Biol. Chem., 271, 13175-13183.
33. CONSTANTINESCU, C.S., WYSOCKA, M., HILLIARD, B., VENTURA, E.S., LAVI, E., TRINCHIERI, G. & ROSTAMI, A. (1998). Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J. Immunol., 161, 5097-5104.
34. CRAVATT, B.F., DEMAREST, K., PATRICELLI, M.P., BRACEY, M.H., GIANG, D.K., MARTIN, B.R. & LICHTMAN, A.H. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U.S.A., 98, 9371-9376.
35. CRAVATT, B.F., GIANG, D.K., MAYFIELD, S.P., BOGER, D.L., LERNER, R.A. & GILULA, N.B. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 384, 83-87.
36. CROSS, A.H., TROTTER, J.L. & LYONS, J. (2001). B cells and antibodies in CNS demyelinating disease. J. Neuroimmunol., 112, 1-14.
37. CROXFORD, J.L. & MILLER, S.D. (2003). Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R + WIN55,212. J. Clin. Invest., 111, 1231-1240.
38. CUZNER, M.L. & OPDENAKKER, G. (1999). Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J. Neuroimmunol., 94, 1-14.
39. DAJANI, E.Z., LARSEN, K.R., TAYLOR, J., DAJANI, N.E., SHAHWAN, T.G., NEELEMAN, S.D., TAYLOR, M.S., DAYTON, M.T. & MIR, G.N. (1999). 1′,1′-Dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties. J. Pharmacol. Exp. Ther., 291, 31-38.
40. DAL CANTO, M.C. & LIPTON, H.L. (1977). A new model of persistent viral infection with primary demyelination. Neurol. Neurocir. Psiquiatr., 18, 455-467.
41. DAY, T.A., RAKHSHAN, F., DEUTSCH, D.G. & BARKER, E.L. (2001). Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol. Pharmacol., 59, 1369-1375.
42. DE KEYSER, J., ZEINSTRA, E. & FROHMAN, E. (2003). Are astrocytes central players in the pathophysiology of multiple sclerosis? Arch. Neurol., 60, 132-136.
43. DEROCQ, J.M., JBILO, O., BOUABOULA, M., SEGUI, M., CLERE, C. & CASELLAS, P. (2000). Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J. Biol. Chem., 275, 15621-15628.
44. DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
45. DI MARZO, V., BISOGNO, T., DE PETROCELLIS, L., MELCK, D. & MARTIN, B.R. (1999a). Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. Curr. Med. Chem., 6, 721-744.
46. DI MARZO, V., BISOGNO, T., DE PETROCELLIS, L., MELCK, D., ORLANDO, P., WAGNER, J.A. & KUNOS, G. (1999b). Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem., 264, 258-267.
47. DI MARZO, V., BISOGNO, T., SUGIURA, T., MELCK, D. & DE PETROCELLIS, L. (1998). The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal-and basophil-like cells: connections with anandamide. Biochem. J., 331, 15-19.
48. DI MARZO, V., BREIVOGEL, C.S., TAO, Q., BRIDGEN, D.T., RAZDAN, R.K., ZIMMER, A.M., ZIMMER, A. & MARTIN, B.R. (2000). Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem., 75, 2434-2444.
49. DI MARZO, V., DE PETROCELLIS, L., BISOGNO, T. & MAURELLI, S. (1997). The endogenous cannabimimetic eicosanoid, anandamide, induces arachidonate release in J774 mouse macrophages. Adv. Exp. Med. Biol., 407, 341-346.
50. DINH, T.P., CARPENTER, D., LESLIE, F.M., FREUND, T.F., KATONA, I., SENSI, S.L., KATHURIA, S. & PIOMELLI, D. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U.S.A., 99, 10819-10824.
51. DONG, Y. & BENVENISTE, E.N. (2001). Immune function of astrocytes. Glia, 36, 180-190.
52. DUSART, I. & SCHWAB, M.E. (1994). Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur. J. Neurosci., 6, 712-724.
53. FACCHINETTI, F., DEL GIUDICE, E., FUREGATO, S., PASSAROTTO, M. & LEON, A. (2003). Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia, 41, 161-168.
54. FELDER, C.C., BRILEY, E.M., AXELROD, J., SIMPSON, J.T., MACKIE, K. & DEVANE, W.A. (1993). Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. U.S.A., 90, 7656-7660.
55. FELDER, C.C., JOYCE, K.E., BRILEY, E.M., MANSOURI, J., MACKIE, K., BLOND, O., LAI, Y., MA, A.L. & MITCHELL, R.L. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol., 48, 443-450.
56. FEZZA, F., BISOGNO, T., MINASSI, A., APPENDINO, G., MECHOULAM, R. & DI MARZO, V. (2002). Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett., 513, 294-298.
57. FOWLER, C.J. & JACOBSSON, S.O. (2002). Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide -targets for drug development? Prostaglandins Leukot. Essent. Fatty Acids, 66, 193-200.
58. FRANKLIN, A., PARMENTIER-BATTEUR, S., WALTER, L., GREENBERG, D.A. & STELLA, N. (2003). Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J. Neurosci., 23, 7767-7775.
59. FU, J., GAETANI, S., OVEISI. F., LO VERME, J., SERRANO, A., RODRIGUEZ DE FONSECA, F., ROSENGARTH, A., LUECKE, H., DI GIACOMO, B., TARZIA, G. & PIOMELLI, D. (2003). Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature, 425, 90-93.
60. GALIEGUE, S., MARY, S., MARCHAND, J., DUSSOSSOY, D., CARRIERE, D., CARAYON, P., BOUABOULA, M., SHIRE, D., LE FUR, G. & CASELLAS, P. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 232, 54-61.
61. GALLILY, R., BREUER, A. & MECHOULAM, R. (2000). 2- Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur. J. Pharmacol., 406, 5-7.
62. GARDNER, B., ZU, L.X., SHARMA. S., LIU, Q., MAKRIYANNIS, A., TASHKIN, D.P. & DUBINETT, S.M. (2002). Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. Biochem. Biophys. Res. Commun., 290, 91-96.
63. GATLEY, S.J., LAN, R., PYATT, B., GIFFORD, A.N., VOLKOW, N.D. & MAKRIYANNIS, A. (1997). Binding of the non-classical cannabinoid CP55,940, and the diarylpyrarole AM251 to rodent brain cannabinoid receptor. Life Sci., 61, PL191-PL197.
64. GENDELMAN, H.E., GENIS, P., JETT, M., ZHAI, Q.H. & NOTTET, H.S. (1994). An experimental model system for HIV-1-induced brain injury. Adv. Neuroimmunol., 4, 189-193.
65. GERARD, C.M., MOLLEREAU, C., VASSART, G. & PARMENTIER, M. (1991). Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J., 279, 129-134.
66. GLASER, S.T., ABUMRAD, N.A., FATADE, F., KACZOCHA, M., STUDHOLME, K.M. & DEUTSCH, D.G. (2003). Evidence against the presence of an anandamide transporter. Proc. Natl. Acad. Sci. U.S.A., 100, 4269-4274.
67. GRECO, A., MINGHETTI, L. & LEVI, G. (2000). Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem. Res., 35, 1357-1364.
68. GRIFFIN, G., WRAY, E.J., TAO, Q., MCALLISTER, S.D., RORRER, W.K., AUNG, M.M., MARTIN, B.R. & ABOOD, M.E. (1999). Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur. J. Pharmacol., 377, 117-125.
69. HAJOS, N. & FREUND, T.F. (2002). Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology, 43, 503-510.
70. HANUS, L., ABU-LAFI, S., FRIDE, E., BREUER, A., VOGEL, Z., SHALEV, D.E., KUSTANOVICH, I. & MECHOULAM, R. (2001). 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U.S.A., 98, 3662-3665.
71. HANUS, L., BREUER, A., TCHILIBON, S., SHILOAH, S., GOLDENBERG, D., HOROWITZ, M., PERTWEE, R.G., ROSS, R.A., MECHOULAM, R. & FRIDE, E. (1999). HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U.S.A., 96, 14228-14233.
72. HEMMER, B., CEPOK, S., NESSLER, S. & SOMMER, N. (2002). Pathogenesis of multiple sclerosis: an update on immunology. Curr. Opin. Neurol., 15, 227-231.
73. HILLARD, C.J. & JARRAHIAN, A. (2000). The movement of N-arachidonoylethanolamide (anandamide) across cellular membranes. Chem. Phys. Lipids, 108, 123-134.
74. HILLARD, C.J., MANNA, S., GREENBERG, M.J., DICAMELLI, R., ROSS, R.A., STEVENSON, L.A., MURPHY, V., PERTWEE, R.G. & CAMPBELL, W.B. (1999). Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther., 289, 1427-1433.
75. HOWLETT, A.C., BARTH, F., BONNER, T.I., CABRAL, G., CASELLAS, P., DEVANE, W.A., FELDER, C.C., HERKENHAM, M., MACKIE, K., MARTIN, B.R., MECHOULAM, R. & PERTWEE, R.G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161-202.
76. HUNTER, S.A. & BURSTEIN, S.H. (1997). Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. Life Sci., 60, 1563-1573.
77. JARAI, Z., WAGNER, J.A., GOPARAJU, S.K., WANG, L., RAZDAN, R.K., SUGIURA, T., ZIMMER, A.M., BONNER, T.I., ZIMMER, A. & KUNOS, G. (2000). Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice. Hypertension, 35, 679-684.
78. JARAI, Z., WAGNER, J.A., VARGA, K., LAKE, K.D., COMPTON, D.R., MARTIN, B.R., ZIMMER, A.M., BONNER, T.I., BUCKLEY, N.E., MEZEY, E., RAZDAN, R.K., ZIMMER, A. & KUNOS, G. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U.S.A., 96, 14136-14141.
79. JBILO, O., DEROCQ, J.M., SEGUI, M., LE FUR, G. & CASELLAS, P. (1999). Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60. FEBS Lett., 448, 273-277.
80. JEON, Y.J., YANG, K.H., PULASKI, J.T. & KAMINSKI, N.E. (1996). Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-kappa B/Rel activation. Mol. Pharmacol., 50, 334-341.
81. JORDA, M.A., VERBAKEL, S.E., VALK, P.J., VANKAN-BERKHOUDT, Y.V., MACCARRONE, M., FINAZZI-AGRO, A., LOWENBERG, B. & DELWEL, R. (2002). Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood, 99, 2786-2793.
82. KITAMURA, Y., TANIGUCHI, T., KIMURA, H., NOMURA, Y. & GEBICKE-HAERTER, P.J. (2000). Interleukin-4-inhibited mRNA expression in mixed rat glial and in isolated microglial cultures. J. Neuroimmunol., 106, 95-104.
83. KLEGERIS, A., BISSONNETTE, C.J. & MCGEER, P.L. (2003). Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br. J. Pharmacol., 139, 775-786.
84. KLEIN, T.W., NEWTON, C., LARSEN, K., LU, L., PERKINS, I., NONG, L. & FRIEDMAN, H. (2003). The cannabinoid system and immune modulation. J. Leukocyte Biol., 74, 486-496.
85. KLEIN, T.W., NEWTON, C.A., NAKACHI, N. & FRIEDMAN, H. (2000). Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J. Immunol., 164, 6461-6466.
86. KORNEK, B. & LASSMAN, H. (2003). Neuropathology of multiple sclerosis - new concepts. Brain Res. Bull., 61, 321-326.
87. KREUTZBERG, G.W. (1996). Microglia: a sensor for pathological events in the CNS. Trends Neurosci., 19, 312-318.
88. LAMAN, J.D., DE BOER, M. & HART, B.A. (1998). CD40 in clinical inflammation: from multiple sclerosis to atherosclerosis. Dev. Immunol., 6, 215-222.
89. LAMBERT, D.M., DIPAOLO, F.G., SONVEAUX, P., KANYONYO, M., GOVAERTS, S.J., HERMANS, E., BUEB, J., DELZENNE, N.M. & TSCHIRHART, E.J. (1999). Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochim. Biophys. Acta, 1440, 266-274.
90. LAMBERT, D.M., VANDEVOORDE, S., JONSSON, K.O. & FOWLER, C.J. (2002). The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr. Med. Chem., 9, 663-674.
91. LENZLINGER, P.M., MORGANTI-KOSSMANN, M.C., LAURER, H.L. & MCINTOSH, T.K. (2001). The duality of the inflammatory response to traumatic brain injury. Mol. Neurobiol., 24, 169-181.
92. LIN, S., KHANOLKAR, A.D., FAN, P., GOUTOPOULOS, A., QIN, C., PAPAHADJIS, D. & MAKRIYANNIS, A. (1998). Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J. Med. Chem., 41, 5353-5361.
93. LITTLE, P.J., COMPTON, D.R., JOHNSON, M.R., MELVIN, L.S. & MARTIN, B.R. (1988). Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J. Pharmacol. Exp. Ther., 247, 1046-1051.
94. LIU, J., BATKAI, S., PACHER, P., HARVEY-WHITE, J., WAGNER, J.A., CRAVATT, B.F., GAO, B. & KUNOS, G. (2003). LPS induces anandamide synthesis in macrophages via CD14/MAPK/PI3K/NF-kappaB independently of platelet activating factor. J. Biol. Chem., 278, 45034-45039.
95. LIU, J., LI, H., BURSTEIN, S.H., ZURIER, R.B. & CHEN, J.D. (2003). Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol. Pharmacol., 63, 983-992.
96. LODDICK, S.A., LIU, C., TAKAO, T., HASHIMOTO, K. & DE SOUZA, E.B. (1998). Interleukin-1 receptors: cloning studies and role in central nervous system disorders. Brain Res. Brain Res. Rev., 26, 306-319.
97. LYMAN, W.D., SONETT, J.R., BROSNAN, C.F., ELKIN, R. & BORNSTEIN, M.B. (1989). Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol., 23, 73-81.
98. MACCARRONE, M., DE PETROCELLIS, L., BARI, M., FEZZA, F., SALVATI, S., DI MARZO, V. & FINAZZI-AGRO, A. (2001). Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch. Biochem. Biophys., 393, 321-328.
99. MACCARRONE, M., DI RIENZO, M., FINAZZI-AGRO, A. & ROSSI, A. (2003). Leptin activates the anandamide hydrolase promoter in human T lymphocytes through STAT3. J. Biol. Chem., 278, 13318-13324.
100. MACCARRONE, M., FIORUCCI, L., ERBA, F., BARI, M., FINAZZI-AGRO, A. & ASCOLI, F. (2000a). Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. FEBS Lett., 468, 176-180.
101. MACCARRONE, M., LORENZON, T., BARI, M., MELINO, G. & FINAZZI-AGRO, A. (2000b). Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem., 275, 31938-31945.
102. MAHAD, D.J. & RANSOHOFF, R.M. (2003). The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin. Immunol., 15, 23-32.
103. MALFAIT, A.M., GALLILY, R., SUMARIWALLA, P.F., MALIK, A.S., ANDREAKOS, E., MECHOULAM, R. & FELDMANN, M. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U.S.A., 97, 9561-9566.
104. MARTINO, G., ADORINI, L., RIECKMANN, P., HILLERT, J., KALLMANN, B., COMI, G. & FILIPPI, M. (2002). Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol., 1, 499-509.
105. MATIAS, I., POCHARD, P., ORLANDO, P., SALZET, M., PESTEL, J. & DI MARZO, V. (2002). Presence and regulation of the endocannabinoid system in human dendritic cells. Eur. J. Biochem., 269, 3771-3778.
106. MATSUDA, L.A., LOLAIT, S.J., BROWNSTEIN, M.J., YOUNG, A.C. & BONNER, T.I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564.
107. MCGEER, P.L. & ROGERS, J. (1992). Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology, 42, 447-449.
108. MECHOULAM, R., BEN-SHABAT, S., HANUS, L., LIGUMSKY, M., KAMINSKI, N.E., SCHATZ, A.R., GOPHER, A., ALMOG, S., MARTIN, B.R., COMPTON, D.R., PERTWEE, R.G., GRIFFIN, G., GAYEWITCH, M., BARG, J. & VOGEL, Z. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 50, 83-90.
109. MOLDRICH, G. & WENGER, T. (2000). Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides, 21, 1735-1742.
110. MOLINA-HOLGADO, E., VELA, J.M., AREVALO-MARTIN, A., ALMAZAN, G., MOLINA-HOLGADO, F., BORRELL, J. & GUAZA, C. (2002a). Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci., 22, 9742-9753.
111. MOLINA-HOLGADO, F., LLEDO, A. & GUAZA, C. (1997). Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport, 8, 1929-1933.
112. MOLINA-HOLGADO, F., MOLINA-HOLGADO, E. & GUAZA, C. (1998). The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett., 433, 139-142.
113. MOLINA-HOLGADO, F., MOLINA-HOLGADO, E., GUAZA, C. & ROTHWELL, N.J. (2002b). Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J. Neurosci. Res., 61, 829-836.
114. MOLINA-HOLGADO, F., PINTEAUX, E., MOORE, J.D., MOLINA-HOLGADO, E., GUAZA, C., GIBSON, R.M. & ROTHWELL, N.J. (2003). Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci., 23, 6470-6474.
115. MUNRO, S., THOMAS, K.L. & ABU-SHAAR, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65.
116. NEWTON, C.A., KLEIN, T.W. & FRIEDMAN, H. (1994). Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect. Immunol., 62, 4015-4020.
117. OKA, S., TSUCHIE, A., TOKUMURA, A., MURAMATSU, M., SUHARA, Y., TAKAYAMA, H., WAKU, K. & SUGIURA, T. (2003). Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J. Neurochem., 85, 1374-1381.
118. PARKINSON, J.F., MITROVIC, B. & MERRILL, J.E. (1997). The role of nitric oxide in multiple sclerosis. J. Mol. Med., 75, 174-186.
119. PAROLARO, D. (1999). Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci., 65, 637-644.
120. PESTONJAMASP, V.K. & BURSTEIN, S.H. (1998). Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochim. Biophys. Acta, 1394, 249-260.
121. PIOMELLI, D. (2003). The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci., 4, 873-884.
122. PONTI, W., RUBINO, T., BARDOTTI, M., POLI, G. & PAROLARO, D. (2001). Cannabinoids inhibit nitric oxide production in bone marrow derived feline macrophages. Vet. Immunol. Immunopathol., 82, 203-214.
123. POPKO, B., CORBIN, J.G., BAERWALD, K.D., DUPREE, J. & GARCIA, A.M. (1997). The effects of interferon-gamma on the central nervous system. Mol. Neurobiol., 14, 19-35.
124. PRATT, B.M. & MCPHERSON, J.M. (1997). TGF-beta in the central nervous system: potential roles in ischemic injury and neurodegenerative diseases. Cytokine Growth Factor Rev., 8, 267-292.
125. PRYCE, G., AHMED, Z., HANKEY, D.J., JACKSON, S.J., CROXFORD, J.L., POCOCK, J.M., LEDENT, C., PETZOLD, A., THOMPSON, A.J., GIOVANNONI, G., CUZNER, M.L. & BAKER, D. (2003). Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain, 126, 2191-2202.
126. PUFFENBARGER, R.A., BOOTHE, A.C. & CABRAL, G.A. (2000). Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia, 29, 58-69.
127. RAIVICH, G., BOHATSCHEK, M., KLOSS, C.U., WERNER, A., JONES, L.L. & KREUTZBERG, G.W. (1999). Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res. Brain Res. Rev., 30, 77-105.
128. RHEE, M.H., VOGEL, Z., BARG, J., BAYEWITCH, M., LEVY, R., HANUS, L., BREUER, A. & MECHOULAM, R. (1997). Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J. Med. Chem., 40, 3228-3233.
129. RINALDI-CARMONA, M., BARTH, F., HEAULME, M., SHIRE, D., CALANDRA, B., CONGY, C., MARTINEZ, S., MARUANI, J., NELIAT, G., CAPUT, D., FERRARA, P., SOUBRIE, P., BRELIERE, J.C. & LEFUR, G. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 350, 240-244.
130. RINALDI-CARMONA, M., BARTH, F., MILLAN, J., DEROCQ, J.M., CASELLAS, P., CONGY, C., OUSTRIC, D., SARRAN, M., BOUABOULA, M., CALANDRA, B., PORTIER, M., SHIRE, D., BRELIERE, J.C. & LE FUR, G.L. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther., 284, 644-650.
131. RINALDI-CARMONA, M., PIALOT, F., CONGY, C., REDON, E., BARTH, F., BACHY, A., BRELIERE, J.C., SOUBRIE, P. & LE FUR, G. (1996). Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci., 58, 1239-1247.
132. RODRIGUEZ, J.J., MACKIE, K. & PICKEL, V.M. (2001). Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat caudate putamen nucleus. J. Neurosci., 21, 823-833.
133. ROMERO, J., HILLARD, C.J., CALERO, M. & RABANO, A. (2002). Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Brain Res. Mol. Brain Res., 100, 85-93.
134. ROSS, R.A., BROCKIE, H.C. & PERTWEE, R.G. (2000). Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur. J. Pharmacol., 401, 121-130.
135. ROTHWELL, N.J. & LUHESHI, G.N. (2000). Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci., 23, 618-625.
136. SACERDOTE, P., MASSI, P., PANERAI, A.E. & PAROLARO, D. (2000). In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J. Neuroimmunol., 109, 155-163.
137. SAGAN, S., VENANCE, L., TORRENS, Y., CORDIER, J., GLOWINSKI, J. & GIAUME, C. (1999). Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur. J. Neurosci., 11, 691-699.
138. SALIO, C., DOLY, S., FISCHER, J., FRANZONI, M. & CONRATH, M. (2002). Neuronal and astrocytic localization of the cannabinoid receptor-1 in the dorsal horn of the rat spinal cord. Neurosci. Lett., 329, 13.
139. SANCHEZ, C., GALVE-ROPERH, I., RUEDA, D. & GUZMAN, M. (1998). Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol. Pharmacol., 54, 834-843.
140. SCHWARZ, H., BLANCO, F.J. & LOTZ, M. (1994). Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmunol., 55, 107-115.
141. SEGAL, B.M., DWYER, B.K. & SHEVACH, E.M. (1998). An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med., 187, 537-546.
142. SHIVACHAR, A.C., MARTIN, B.R. & ELLIS, E.F. (1996). Anandamide-and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methyl-1H-pyrazole-3-carboximide hydrochloride]. Biochem. Pharmacol., 51, 669-676.
143. SHOWALTER, V.M., COMPTON, D.R., MARTIN, B.R. & ABOOD, M.E. (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther., 278, 989-999.
144. SIMONEAN, I., HAMZA, M.S., MATA, H.P., SIEGEL, E.M., VANDERAH, T.W., PORRECA, F., MAKRIYANNIS, A. & MALAN, T.P. (2001). The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology, 94, 882-887.
145. SINHA, D., BONNER, T.I., BHAT, N.R. & MATSUDA, L.A. (1998). Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: immunochemical characterization by fusion protein antibodies. J. Neuroimmunol., 82, 13-21.
146. SLIPETZ, D.M., O'NEILL, G.P., FAVREAU, L., DUFRESNE, C., GALLANT, M., GAREAU, Y., GUAY, D., LABELLE, M. & METTERS, K.M. (1995). Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol. Pharmacol., 48, 352-361.
147. SONG, Z.H. & BONNER, T.I. (1996). A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol. Pharmacol., 49, 891-896.
148. STEFANO, G.B., BILFINGER, T.V., RIALAS, C.M. & DEUTSCH, D.G. (2000). 2-arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. Pharmacol. Res., 42, 317-322.
149. STEFANO, G.B., LIU, Y. & GOLIGORSKY, M.S. (1996). Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes. J. Biol. Chem., 271, 19238-19242.
150. STEFANO, G.B., SALZET, M., RIALAS, C.M., MATTOCKS, D., FIMIANI, C. & BILFINGER, T.V. (1998). Macrophage behavior associated with acute and chronic exposure to HIV GP120, morphine and anandamide: endothelial implications. Int. J. Cardiol., 64, 3-13.
151. STELLA, N., SCHWEITZER, P. & PIOMELLI, D. (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature, 388, 773-778.
152. SUGIURA, T., KONDO, S., KISHIMOTO, S., MIYASHITA, I., NAKANE, S., KODATA, T., SUHERA, T., TAKAYAMA, H. & WAKU, K. (2000). Evidence that z-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem., 275, 605-612.
153. SUGIURA, T., KONDO, S., SUKAGAWA, A., NAKANE, S., SHINODA, A., ITOH, K., YAMASHITA, A. & WAKU, K. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun., 215, 89-97.
154. TAO, Q. & ABOOD, M.E. (1998). Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors. CB1 and CB2. disrupts G-protein coupling. J. Pharmacol. Exp. Ther., 285, 651-658.
155. VARGA, K., WAGNER, J.A., BRIDGEN, D.T. & KUNOS, G. (1998). Platelet-and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J., 12, 1035-1044.
156. WAGNER, J.A., VARGA, K., ELLIS, E.F., RZIGALINSKI, B.A., MARTIN, B.R. & KUNOS, G. (1997). Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature, 390, 518-521.
157. WAKSMAN, Y., OLSON, J.M., CARLISLE, S.J. & CABRAL, G.A. (1999). The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J. Pharmacol. Exp. Ther., 288, 1357-1366.
158. WALTER, L., FRANKLIN, A., WITTING, A., MOLLER, T. & STELLA, N. (2002). Astrocytes in culture produce anandamide and other acylethanolamides. J. Biol. Chem., 26, 26.
159. WALTER, L., FRANKLIN, A., WITTING, A., WADE, C., XIE, Y., KUNOS, G., MACKIE, K. & STELLA, N. (2003a). Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci., 23, 1398-1405.
160. WALTER, L. & STELLA, N. (2003b). Endothelin-1 increases 2-arachidonoyl glycerol (2-AG) production in astrocytes. Glia, 44, 85-90.
161. WARTMANN, M., CAMPBELL, D., SUBRAMANIAN, A., BURSTEIN, S.H. & DAVIS, R.J. (1995). The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett., 359, 133-136.
162. WILLOUGHBY, K.A., MOORE, S.F., MARTIN, B.R. & ELLIS, E.F. (1997). The biodisposition and metabolism of anandamide in mice. J. Pharmacol. Exp. Ther., 282, 243-247.
163. WIRGUIN, I., MECHOULAM, R., BREUER, A., SCHEZEN, E., WEIDENFELD, J. & BRENNER, T. (1994). Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology, 28, 209-214.
164. WYSS-CORAY, T., LIN, C., YAN, F., YU, G.Q., ROHDE, M., MCCONLOGUE, L., MASLIAH, E. & MUCKE, L. (2001). TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med., 7, 612-618.
165. YUAN, M., KIERTSCHER, S.M., CHENG, Q., ZOUMALAN, R., TASHKIN, D.P. & ROTH, M.D. (2002). Delta 9-tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J. Neuroimmunol., 133, 124-131.
166. ZAMVIL, S.S. & STEINMAN, L. (1990). The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol., 8, 579-621.
167. ZHANG, J., HOFFERT, C., VU, H.K., GROBLEWSKI, T., AHMAD. S. & O'DONNELL, D. (2003). Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur. J. Neurosci., 17, 2750-2754.
168. ZHU, W., FRIEDMAN, H. & KLEIN, T.W. (1998). Delta9- tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1. J. Pharmacol. Exp. Ther., 286, 1103-1109.
169. ZIMMER, A., ZIMMER, A.M., HOHMANN, A.G., HERKENHAM, M. & BONNER, T.I. (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A., 96, 5780-5785.
170. ZURIER, R.B., ROSSETTI, R.G., BURSTEIN, S.H. & BIDINGER, B. (2003). Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem. Pharmacol., 65, 649-655.